Optimizing cancer treatments to induce an acute immune response: Radiation abscopal effects, PAMPs, and DAMPs

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4522-4525

  Ludgate, Charles M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 2; IPILIMUMAB; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ABSCOPAL EFFECT; ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER THERAPY; DAMAGE ASSOCIATED MOLECULAR PATTERN; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; KIDNEY CARCINOMA; MELANOMA; METASTATIC MELANOMA; MOLECULAR INTERACTION; NONHUMAN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION NECROSIS; RADIATION RESPONSE; REVIEW; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR NECROSIS;

CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; HORMONES; HUMANS; IMMUNITY, INNATE; MALE; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RADIOTHERAPY; RNA, BACTERIAL;

EID: 84865782617     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1175     Document Type: Review

References (26)

1. Ludgate C, Bishop D, Pai H, Eldridge B, Lim J, Berthelet E, et al. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation. Int J Radiat Oncol Biol Phys 2005;62:1309-15.
2. D'Amico A, Whittington R, Malkowicz S, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
3. Albertsen P, Hanley J, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
4. Alexander A, Mydin A, Jones S, Christie J, Lim JT, Truong PT, et al. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA) >40 ng/ml: prognostic significance of the preradiation PSA nadir. Int J Radiat Oncol Biol Phys 2011:81:713-9.
5. Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P , et al. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 2010;76:23-30.
6. Demaria S, Ng B, Devitt M, Babb JS, Kawashima N, Liebes L, et al. Ionising radiation inhibition of distant untreated tumors (Abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58:862-70.
7. Hoption Cann S, vanNetten J, vanNetten C, Dr William. Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003;79:672-80.
8. Palm N, Medhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009;227:221-33.
9. Bianchi M. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leucoc Biol 2007;81:1-5.
10. Della Chiesa M, Sivori S, Castriconi R, Marcenaro E, Moretta A. Pathogen-induced private conversations between natural killer and dendritic cells. Trends Microbiol 2005;13:128-36.
11. Holzman D. New data cheer champions of the danger theory. J Natl Cancer Inst 2010;102:76-8.
12. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002;195:9-14.
13. Mace TA, Zhong L, Kilpatrick C, Zynda E, Lee CT, Capitano M, et al. Differentiation of CD8+ T cells into effector cells is enhanced by physiological range hyperthermia. J. Leukoc Biol 2011;90:951-62.
14. Wick D, Martin S, Nelson B, Webb J. Profound CD8(+) T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 2011;29:984-93.
15. Wick D, Webb J. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine 2011;29:7857-66.
16. Ngoi S, Tovey M, Vella A. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-α/β1. J Immunol 2008;181:7670-80.
17. Fujimoto N, Kubo T, Shinsaka H, Matsumoto M, Shimajiri S, Matsumoto T. Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer. BMC Urol 2011;11:7,1471-2490. Available from: http://www.biomedcentral.com/1471-2490/11/7.
18. Antalis T, Buzza M, Hodge K, Hooper J, Netzel-Arnett S. The cutting edge: membrane-anchored serine protease activities in thepericellular microenvironment. Biochem J 2010;428:325-46.
19. NUtsunomiya N, Nakanishi M.Aserine protease triggers the initial step of transmembrane signalling in cytotoxic T cells. J Biol Chem 1986;261:16514-7.
20. Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, et al. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 2011;70-82.
21. Garg DA, Nowis D, Golab Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010;1805:53-71.
22. Shiao S, Coussens L. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010;15:411-21.
23. Eriksson D, Stigbrand T. Radiation induced cell deaths mechanisms. Tumor Biol 2010;31:363-72.
24. Pruitt S, Boczkowski D, de Rosa N. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol 2011;41:3553-63.
25. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the Abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-31.
26. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC. Phase 1 study of stereotactic body radiotherapy and interleukin-2: tumor and immunological responses. Sci Transl Med 2012;4:137ra74.